左心耳（LAA）デバイスの世界市場-2022-2029年

市場力学

不整脈患者の増加による市場の拡大が見込まれる

左心耳（LAA）デバイス市場は、世界中の新興経済諸国において2桁成長を遂げると予測されています。高い成長率は、心房細動やその他の不整脈に苦しむ患者数が継続的に増加していることに起因していると認識されています。先進国では心房細動のリスクが高いため、左心房付属器に対する需要が高まり、左心耳（LAA）デバイス市場の成長を後押しすることになります。さらに、心調律障害、糖尿病、高血圧の有病率の増加が、予測期間中に左心耳（LAA）デバイス市場の需要を増加させると予想されます。

さらに、政府が心不整脈に関する意識を高めることに注力することが、左心耳（LAA）デバイス市場に貢献するものと思われます。心調律異常を患う主要な患者群により、LAA（左心房付属器）デバイスの採用率が大幅に上昇しています。脳卒中のリスクを防ぎ、血栓を減らすために、左心房付属器に対する需要が増加しました。

一方、左心耳（LAA）デバイスの高コストが、世界の左心耳（LAA）デバイス市場の妨げになると予想されます。さらに、左心房付属器に関する高コストのため、人々はより手頃な価格の代替ソリューションを好みます。したがって、この要因は予測期間中の市場の成長を阻害します。さらに、左心房付属器に関する償還政策の格差も、世界市場の成長を停滞させると予想されます。

目次

第1章 調査手法と範囲

• 調査手法
• 市場の範囲

第2章 主な動向と発展

第3章 エグゼクティブサマリー

• 製品別市場内訳
• プロシージャ別市場内訳
• エンドユーザー別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響要因
  • 促進要因
  • 抑制要因
  • ビジネスチャンス
• 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• バリューチェーン分析
• 特許分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み

第7章 薬物クラスタイプ別

• 心内膜
• 心外膜

第8章 手技別

• 経皮的
• 外科的

第9章 エンドユーザー別

• 病院
• 外来手術センター
• 心臓クリニック

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 競合他社の戦略分析
• 市況/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Boston Scientific Corporation
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• AtriCure
• Abbott
• Biosense Webster
• Lifetech Scientific
• SentreHEART
• Append Medical
• Cardia
• Johnson & Johnson
• Occlutech

第13章 DataM

Market Overview

Left atrial appendage devices (LAA) market was valued at USD 490 million in 2021. It is forecasted to reach USD million by 2029, growing at a CAGR of 20.2% during the forecast period (2022-2029).

Left atrial appendages (LAA) are the small, ear-shaped sac in the left atrium's muscle wall. The left atrial appendage is a minimally invasive technique that supports lowering the risk of stroke. A high-risk stroke arises due to atrial fibrillation. Left atrial appendage (LAA) devices such as the Amplatzer plug device and watchman device reduce blood clots' probability and prevent heart stroke. The device transplantation is usually achieved under anesthesia with trans-esophageal echo guidance. The growing elderly population and the rising occurrence of atrial fibrillation worldwide are key factors fuel the growth of the left atrial appendage devices (LAA) Market.

Market Dynamics: An increase in the number of arrhythmias patients suffering expected to drive market growth.

The left atrial appendage devices (LAA) Market is estimated to grow with double-digit growth in the developing economies across the globe. The high growth rate is recognized by the continuously growing number of patients suffering from atrial fibrillation and other arrhythmias. There is a high risk for atrial fibrillation in developed countries, which will boost the demand for left atrial appendage devices, which will boost the growth of the left atrial appendage devices (LAA) Market. Furthermore, the growing prevalence of cardiac rhythm disorders, diabetes, and high blood pressure is expected to increase the demand for the left atrial appendage devices (LAA) Market over the forecast period.

Moreover, increasing the government's focus on raising awareness about cardiac arrhythmias will contribute to the left atrial appendage devices (LAA) market. The adoption rate of the LAA (left atrial appendage) devices has increased significantly due to a key patient pool suffering from cardiac rhythm abnormalities. To prevent stroke risk and reduce blood clots, the demand for left atrial appendage devices increased.

On the contrary, the high cost of left atrial appendage (LAA) devices is expected to hamper the global left atrial appendage devices (LAA) Market. Moreover, due to the high cost associated with left atrial appendage devices, people prefer alternative solutions that are more affordable. Thus, this factor hinders the market's growth over the forecast period. Further, the disparity in left atrial appendage devices' reimbursement policies is also expected to stagnant the global market's growth.

Market Segmentation: Hospitals segment accounted for the highest share in global left atrial appendage devices (LAA) market.

The hospital segment is projected to dominate the left atrial appendage devices (LAA) Market due to the increasing numbers of heart-related disease cases across the globe, which propels the demand for specialty hospitals to treat heart-related diseases. Moreover, improving and advancing medical infrastructure is estimated to boost left atrial appendage devices in hospitals. Health spending in the U.S. is projected to have grown 4.2% to $4.3 trillion in 2021 as compared to a growth surge of 9.7% in 2020, according to the data published by actuaries at the Centers for Medicare and Medicaid Services.

The ambulatory surgical center segment is estimated to hold a significant share in the global left atrial appendage devices (LAA) market and grow with a healthy CAGR over the forecast period. Moreover, ambulatory surgical centers have a low cost compared to hospitals. They have minimal risk of infection, estimated to enhance the left atrial appendage devices (LAA) Market.

The epicardial left atrial appendage devices segment is expected to grow with a significant growth rate during the forecast timeframe due to the increasing adoption of these products in developed economies across the globe. Moreover, the epicardial left atrial appendage device can negate the need to implant a permanent device. Also, the epicardial device does not require anticoagulation post-procedure. Thus, due to these several benefits of epicardial left atrial appendage devices, the Market is estimated to create lucrative growth opportunities during the forecast timeframe.

Geographical Penetration: North America is the dominating region during the forecast period.

North America is projected to hold the largest share in the left atrial appendage devices (LAA) market due to the increasing number of atrial fibrillation cases. The increasing atrial fibrillation population in the United with the increasing geriatric population across the nation drives the market growth. Atrial Fibrillation is expected to cause heatstroke, and subsequently, left atrial appendage management is of extreme importance. Additionally, novel technologies are being launched in the market, which is estimated to raise these devices' adoption across the region. US census projections for the next 50 years estimate that about 3 million Americans will have atrial fibrillation by the year 2020, increasing to 5.6 million by the year 2050, with more than half affected age 80 or older.

Competitive Landscape:

The left atrial appendage devices (LAA) market is moderately fragmented with the presence of regional as well as global players. Some of the key players in the growth of the market include Boston Scientific Corp., AtriCure, Abbott, Biosense Webster, Lifetech Scientific, SentreHEART and Append Medical among others. The key players are executing several growth strategies, such as product launches, acquisitions, and collaborations, which are expected to fuel the global left atrial appendage devices (LAA) market. In July 2020, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. This device helps to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative therapy. In April 2022, Abbott announced the U.S. availability of its Amplatzer steerable delivery sheath device. It is used with the company's Amplatzer Amulet left atrial appendage (LAA) occluder is used to treat people with atrial fibrillation (AFib) to reduce the risk of ischaemic stroke. U.S. physicians now have more flexibility and precise placement when implanting the Amulet device in simple and complex anatomies.

COVID-19 Impact: Positive impact on the global left atrial appendage devices (LAA) market

The left atrial appendage device (LAA) market is estimated to experience a surge in the left atrial appendage market's growth rate. Several countries' governments and private organizations are taking initiatives to create awareness among the population during this pandemic. These factors are projected to increase the growth of the left atrial appendage market. Along with this factor, manufacturers focused on developing new products to gain a strong position in the global market during a pandemic. Due to the pandemic, there is a rise in the number of ambulatory clinical centers globally. The advancement of products by key manufacturers is expected to boost the growth left atrial appendage market.

The global left atrial appendage devices (LAA) market report would provide an access to approximately 61 market data tables, 50 figures and 170 pages

Table of Contents

Scope and Methodology

• 1.1. Research Methodology
• 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

• 3.1. Market Snippet by Product
• 3.2. Market Snippet by Procedure
• 3.3. Market Snippet by End-Use
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market impacting factors
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
• 4.2. Impact analysis

5. Industry Analysis

• 5.1. Porter's five forces analysis
• 5.2. Value chain analysis
• 5.3. Patent Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives

7. By Drug Class Type

• 7.1. Introduction
  • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Segment
  • 7.1.2. Market attractiveness index, By Product Segment
• 7.2. Endocardial *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 7.3. Epicardial

8. By Procedure

• 8.1. Introduction
  • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Procedure Segment
  • 8.1.2. Market attractiveness index, By Procedure Segment
• 8.2. Percutaneous*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 8.3. Surgical

9. By End Use

• 9.1. Introduction
  • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By End Use Segment
  • 9.1.2. Market attractiveness index, By End Use Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 9.3. Ambulatory Surgical Centers
• 9.4. Heart Clinics

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key region-specific dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
  • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. South America
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
  • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.3.6.1. Brazil
    • 10.3.6.2. Argentina
    • 10.3.6.3. Rest of South America
• 10.4. Europe
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
  • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.4.6.1. Germany
    • 10.4.6.2. U.K.
    • 10.4.6.3. France
    • 10.4.6.4. Spain
    • 10.4.6.5. Italy
    • 10.4.6.6. Rest of Europe
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
  • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use

11. Competitive Landscape

• 11.1. Competitive scenario
• 11.2. Competitor strategy analysis
• 11.3. Market positioning/share analysis
• 11.4. Mergers and acquisitions analysis

12. Company Profiles

• 12.1. Boston Scientific Corporation*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. AtriCure
• 12.3. Abbott
• 12.4. Biosense Webster
• 12.5. Lifetech Scientific
• 12.6. SentreHEART
• 12.7. Append Medical
• 12.8. Cardia
• 12.9. Johnson & Johnson
• 12.10. Occlutech
• List not Exhaustive*

13. DataM

• 13.1. Appendix
• 13.2. About us and services
• 13.3. Contact us